Lucentis 0.23mg

Lucentis 0.23mg

700.00

Lucentis 0.23mg

Category

Lucentis 0.23mg is a medication used to treat a variety of eye conditions, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). The active ingredient in Lucentis 0.23mg is ranibizumab, a recombinant humanized monoclonal antibody that binds to and inhibits vascular endothelial growth factor (VEGF). VEGF is a protein that is involved in the growth of new blood vessels, and when it is overproduced, it can lead to the development of abnormal blood vessels in the eye.

Lucentis 0.23mg is administered as an injection directly into the affected eye by a healthcare professional. The recommended dosage is 0.5mg (which is equivalent to 0.05ml) injected into the eye once a month, but this can vary depending on the condition being treated and the patient’s individual response to the medication.

Lucentis 0.23mg is a prescription medication, and it should only be used under the supervision of a qualified healthcare professional. Before starting treatment with Lucentis 0.23mg, patients should inform their doctor of any medical conditions they have, any medications they are taking, and any allergies they have, particularly to medications that contain albumin. Lucentis 0.23mg should not be used in patients who have an active infection in or around the eye, or in patients who are allergic to ranibizumab or any of the other ingredients in the medication.

Common side effects of Lucentis 0.23mg include eye pain, redness, or discomfort, floaters in the vision, and changes in vision. These side effects are usually mild and temporary, and they typically resolve on their own within a few days. However, patients who experience more serious side effects, such as severe eye pain or sudden vision loss, should seek immediate medical attention.

In summary, Lucentis 0.23mg is a medication used to treat several eye conditions, including wet age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion. It is administered as an injection into the affected eye by a healthcare professional, and it works by inhibiting the growth of abnormal blood vessels in the eye. While Lucentis 0.23mg can have some mild and temporary side effects, it is generally well-tolerated and can be an effective treatment option for patients with certain eye conditions.

Brand

Lucentis

Lucentis is a brand of medication used to treat various eye conditions, including neovascular (wet) age-related macular degeneration, diabetic macular edema, and macular edema due to retinal vein occlusion. The brand is produced by Genentech, a subsidiary of the Swiss pharmaceutical company Roche. Lucentis contains the active ingredient ranibizumab, which is a recombinant humanized monoclonal antibody fragment. It works by blocking the activity of vascular endothelial growth factor (VEGF), a protein that promotes the growth of abnormal blood vessels in the eye. By inhibiting VEGF, Lucentis can help to reduce the formation of these abnormal blood vessels and improve vision in people with certain eye conditions. Lucentis is administered by injection into the eye, typically by a healthcare professional such as an ophthalmologist. The frequency and duration of treatment depend on the individual's specific condition and response to treatment. During treatment, patients will need to have regular eye exams and follow-up appointments to monitor their progress and adjust their treatment plan as needed.
Lucentis

Reviews

There are no reviews yet.

Be the first to review “Lucentis 0.23mg”

Your email address will not be published. Required fields are marked *

Shopping Cart
× How can I help you?